



Medication Trend Updates and Preferred Drug List Changes – 2nd Quarter 2021

Review changes that improve patient safety and encourage medication adherence

Stay up-to-date with information about:

- Patent expiration for commonly used brand-name medications
- Health Net prefers biosimilars
- Osteoporosis member outreach reports are available
- Changes to the Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company, Inc. commercial *Formulary*, *Medi-Cal Preferred Drug List (PDL)* and Medicare Part D *Formulary* for the second quarter of 2021

Patent expiration for commonly used brand-name medications

Patents are granted by the United States Patent and Trademark Office along the development lifeline of a medication. Patents expire 20 years from the date of filing. Many factors can affect the duration of a patent. When a brand-name medication loses its patent, lower-priced generics enter the market.

The Food and Drug Administration- (FDA-) approved generic drugs are made under the same rigorous standards as their brand-name counterparts and are bioequivalent, delivering the same amount of active ingredients into a patient's bloodstream in the same amount of time as their brand-name product. During the upcoming year, it is anticipated that the key medications listed below will be available as generic equivalents.

Quarter	Medication Patent Expirations for 2021
1st	Amitiza®, Northera®
2nd	Absorica®, Banzel® tablet, Chantix®, Perforomist®
3rd	Bystolic®, Sutent®
4th	Brovana®, Pradaxa®

Health Net prefers biosimilars

The FDA approves safe and effective medicines that are highly similar to existing biologic medicines. The FDA regulates biosimilar manufacturing to ensure they scientifically demonstrate safety and effectiveness while showing no clinically meaningful differences. Since biosimilars tend to cost less than their brand name counterparts, they can help lower the overall cost of care for members while still providing quality care.

THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

LINES OF BUSINESS:

- HMO/POS/HSP
- PPO
- EPO
- Medicare Advantage (HMO)
- Medi-Cal
 - Kern
 - Molina
 - Los Angeles
 - Riverside
 - Sacramento
 - San Bernardino
 - San Diego
 - San Joaquin
 - Stanislaus
 - Tulare

PROVIDER SERVICES
provider_services@healthnet.com

EnhancedCare PPO (IFP)
844-463-8188
provider.healthnetcalifornia.com

EnhancedCare PPO (SBG)
844-463-8188
provider.healthnet.com

Health Net Employer Group HMO, POS, HSP, PPO, & EPO
800-641-7761
provider.healthnet.com

IFP – CommunityCare HMO, PPO, PureCare HSP, PureCare One EPO
888-926-2164
provider.healthnetcalifornia.com

Medicare (individual)
800-929-9224
provider.healthnetcalifornia.com

Medicare (employer group)
800-929-9224
provider.healthnet.com
Medi-Cal – 800-675-6110
provider.healthnet.com

PROVIDER COMMUNICATIONS
provider.communications@healthnet.com

Since September 1, 2020, Health Net has preferred the following biosimilars over their brand counterparts for commercial and Medi-Cal members. Patients must try and fail (or have contraindications to) the preferred biosimilar before the brand name product will be approved.

Reference product (Non-preferred)	Preferred biosimilar(s)
Epogen [®] , Procrit [®] (epoetin alfa)	Retacrit [®] (epoetin alfa-epbx)
Neupogen [®] (filgrastim)	Zarxio [®] (filgrastim-sndz)
Neulasta [®] (peg-filgrastim)* <i>*requires Zarxio[®] step requirement</i>	Ziextenzo [™] (pegfilgrastim-bmez)
Remicade [®]	Inflectra [®] (infliximab-dyyb) Renflexis [®] (infliximab-abda)
Rituxan [®]	Ruxience [®] (rituximab-pvvr)
Avastin [®] (for non-ophthalmic diagnoses)	Mvasi [™] (bevacizumab-awwb) Zirabev [™] (bevacizumab-bvcr)
Herceptin [®]	Ogivri [®] (trastuzumab-dkst) Trazimera [™] (trastuzumab-qyyp)

Osteoporosis member outreach reports available

The Management of Post-Menopausal Women with Osteoporotic Fractures Program is a health education outreach and intervention for Health Net Medicare Advantage (MA) female members ages 65 to 85 who have had an osteoporotic fracture in the past three months and have not received a bone-mineral density (BMD) test or are not currently taking prescription medication.

Participating physician groups (PPGs) can access reports with specific Healthcare Effectiveness Data and Information Set (HEDIS[®]) results to find areas for improvement or best practices. The report provides monthly gap lists for specific measures to find gaps in data and drive member gap closure. These reports are available on the Health Net provider portal, as listed in the table on the next page under *Additional information*. For technical help on how to gain access to these reports, contact Health Net's Web Support at 866-458-1047.

Changes to the commercial *Formulary*, Medi-Cal PDL and Medicare Part D *Formulary*

The Health Net Pharmacy and Therapeutics (P&T) Committee, which includes practicing physicians, pharmacists and other health care professionals, reviews medications on the *Formulary* for commercial members, *PDL* for Medi-Cal members and the Medicare Part D *Formulary* for Medicare members each quarter to determine medications to stay on or be moved to a different tier. A list of some recent changes is provided in a table starting on page 4. The list contains brand-name prescription medications, status, other medication choices, and comments for the second quarter of 2021.

Complete lists of the commercial *Formularies*, *Medi-Cal PDLs* and Medicare Part D *Formularies* are available on the Health Net provider website as listed in the table on the next page under *Additional information*.

Pharmacy help line

For more information regarding changes to the Health Net commercial *Formulary*, *Health Net Medi-Cal PDL* or Medicare Part D *Formulary*, contact the proper pharmacy telephone numbers below:

- **Pharmacy Services (commercial):** 800-548-5524, option #3; fax 800-314-6223
- **Pharmacy Services Center (Medi-Cal, Medicare and Cal MediConnect):** 800-867-6564; fax 800-977-8226
- **Health Net Clinical Pharmacy Line (clinical programs):** 800-782-2221

Additional information

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center within 60 days at:

Line of Business	Telephone Number	Provider Portal	Email Address
EnhancedCare PPO (IFP)	844-463-8188	provider.healthnetcalifornia.com	provider_services@healthnet.com
EnhancedCare PPO (SBG)	844-463-8188	provider.healthnet.com	
Health Net Employer Group HMO, POS, HSP, PPO, & EPO	800-641-7761	provider.healthnet.com	
IFP (CommunityCare HMO, PPO, PureCare HSP, PureCare One EPO)	888-926-2164	provider.healthnetcalifornia.com	
Medicare (Individual)	800-929-9224	provider.healthnetcalifornia.com	
Medicare (Employer group)	800-929-9224	provider.healthnet.com	
Medi-Cal	800-675-6110	provider.healthnet.com	N/A

Health Net Commercial *Formulary*, *Medi-Cal PDL* and Medicare Part D *Formulary* Changes

Oral medications

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial Tier 3 plan (Tier 4 plan)	Medicare Part D (6-Tier preferred) ¹	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value ¹ (Tier 1, 2, 3, 4, 5 or 6)	Medi-Cal	
Dojolvi™ (triheptanoin) oral liquid	NF (NF)	NF	NF*				Treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD)
Gavreto™ (pralsetinib) capsule	NF (NF)	Tier 5 ***	NF*		Retevmo™ ***		Treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test
Inqovi® (decitabine/cedazuridine) tablet	NF (NF)	Tier 5 ***	NF*			decitabine (Dacogen®) injection *, **	Treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups

Oral medications, continued

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial Tier 3 plan (Tier 4 plan)	Medicare Part D (6-Tier preferred) ¹	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value ¹ (Tier 1, 2, 3, 4, 5 or 6)	Medi-Cal	
Isturisa® (osilodrostat) tablet	NF (NF)	NF	NF*	Signifor® (* for 4-tier plan)	Signifor *		Treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative
Lampit® (nifurtimox) tablet	NF (NF)	NF	NF*	benznidazole			Pediatric patients (birth to less than age 18 and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by <i>Trypanosoma cruzi</i> (<i>T. cruzi</i>).

Installation preparation

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial Tier 3 plan (Tier 4 plan)	Medicare Part D (6-Tier preferred) ¹	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value ¹ (Tier 1, 2, 3, 4, 5 or 6)	Medi-Cal	
Jelmyto™ (mitomycin for pyelocalyceal solution) single-dose vial	Medical benefit*	Medical benefit*	Medical benefit*				Treatment of adult patients with low-grade upper tract urothelial cancer (LG-UTUC)

Injectable preparations

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial Tier 3 plan (Tier 4 plan)	Medicare Part D (6-Tier preferred) ¹	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value ¹ (Tier 1, 2, 3, 4, 5 or 6)	Medi-Cal	
Uplizna™ (inebilizumab-cdon) single-dose vial	Medical benefit*	Medical benefit*	Medical benefit*		Ruxience™ ***	Soliris®*, **	Treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive
Viltepso™ (viltolarsen) single-dose vial	Medical benefit*	Medical benefit*	Medical benefit*	prednisone	prednisone	prednisone	Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping

¹ Medicare Part D = Health Net Gold Select (HMO), Health Net Healthy Heart (HMO), Health Net Jade (HMO C-SNP), Health Net Ruby (HMO), Health Net Ruby Select (HMO), Health Net Sapphire (HMO), Health Net Violet 1 (PPO), Health Net Violet 2 (PPO), Health Net Violet 3 (PPO), Health Net Violet 4 (PPO)

*Prior authorization (PA) is required to verify member eligibility and that the member satisfies clinical protocols to ensure appropriate use of the medication.

**CCS = California Children's Services: refer to www.dhs.ca.gov for the local telephone number to determine member's coverage eligibility.

***Prior authorization (PA) for new start only is required to verify member eligibility and that the member satisfies clinical protocols to ensure appropriate use of the medication.

- NF indicates nonformulary. These medications require member-specific medical reasons why formulary medications cannot be considered. Requests are reviewed via Health Net's prior authorization process.